Cyclacel Pharmaceuticals, Inc.·4

Feb 2, 4:19 PM ET

McBarron Paul 4

4 · Cyclacel Pharmaceuticals, Inc. · Filed Feb 2, 2023

Insider Transaction Report

Form 4
Period: 2023-01-31
McBarron Paul
DirectorEVP, Finance, CFO, COO
Transactions
  • Award

    Common Stock

    2023-01-31+31,20031,492 total
Footnotes (2)
  • [F1]The reporting person received an award of 31,200 restricted stock units on January 31, 2023, which shall vest in full on January 31, 2026, provided, however, that if certain clinical milestones are achieved then such restricted stock units shall vest in full earlier in connection with such achievement.
  • [F2]Includes 292 shares of common stock and 31,200 restricted stock units.

Documents

1 file
  • 4
    tm235262-3_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT